SGLT-2 inhibitors and risk of 59 long-term health conditions, hospitalisation, and mortality.
BACKGROUND Type 2 diabetes mellitus (T2DM) is often the first condition on the pathway to patients developing multiple long-term conditions (MLTC). The impact of sodium-glucose cotransporter 2 inhibitors (SGLT-2i), a key T2DM treatment, on hospitalisation and MLTC progression remains uncertain. METHODS In this compar...